Humai and Bioquark Join Forces To Combat Blood Reperfusion Injury

 

 

 

 

 

 

 

 

In the 21st century, longevity – the extension of one’s own life – is considered a noble, though fanciful, pursuit. For two companies, however, (Bioquark, Inc. and Humai Technologies LLC.) it’s a pursuit that we can no longer deny. While our efforts to keep a person alive today are indeed quite effective, they aren’t effective enough. Having a stroke or a heart attack? Doctors could intervene through blood reperfusion, though the reperfusion process itself results in further cellular decay. This is what is known as reperfusion injury. And for Bioquark and Humai, it is a problem of which their new partnership can finally help bring an end to.

“We are both connected in our need to solve one of the major unsolved problems that has plagued the healthcare space for decades, costing hundreds of billions of dollars annually – blood reperfusion / reoxygenation injury in critical organ systems – a problem that results in more tissue damage than the initial “insult” (heart attack, stroke, etc.).”

– Ira S. Pastor, CEO of Bioquark

FUTURE IMPLICATIONS

Both companies have made headlines over the course of several months now for their similar goals: bringing people back from the dead. And while they’ve done a good job in getting more people interested in the topic itself, we all sit idly by, waiting…hoping…their goals will soon be met before the grim reaper begins breathing over our own shoulders. With this new partnership, the two can finally begin combating death itself using creative solutions that only the best in modern medical science and technology can provide. If anything, if we are to remain alive a hundred years from now, we can thank both of these companies and their so-called “fanciful” efforts.